Business Wire

NelsonHall Positions L&T Technology Services in the Leaders Category for IoT Services


L&T Technology Services Limited (NSE: LTTS), a leading global pure-play engineering services company announced that it has been positioned in the Leaders Category by independent global research firm, NelsonHall in its latest NEAT evaluation for Internet of Things (IoT) services providers. LTTS is the only global pure-play engineering services to be positioned in the leader’s category.

This press release features multimedia. View the full release here:

L&T Technology Services Capabilities across IoT Services. (Graphic: Business Wire)

L&T Technology Services Capabilities across IoT Services. (Graphic: Business Wire)

LTTS has been identified as a leader relative to its peers’ due to its ability to meet future client requirements as well as deliver immediate benefits to IoT Services clients.

Dominique Raviart, IT Services Practice Director, NelsonHall said, “L&T Technology Services has several strengths that make it relevant to industrial IoT. The company has a background in the manufacturing industry. It is actively expanding its IoT portfolio, and has created its own IoT platform, as well as continuing to create IP-based use cases. Also, LTTS has a background in the ER&D industry, which means that it can provide a continuum of services, from product design and engineering to the IoT platform.”

Mr. Bhupendra Bhate, Chief Operating Officer & Whole Time Director, LTTS commented, “Digital Engineering is shaping things of the future. LTTS as the leading pure play engineering services firm is at the forefront of the digital wave and investing its resources and capabilities in transformative areas such as Embedded Systems & Platforms, Human Machine Interface, Big Data Analytics, Integrated Manufacturing & Asset Management and Design Thinking. Acknowledgements such as this from NelsonHall are a testimony that our strategic focus on new age technology is yielding the desired results.”

NelsonHall’s profile of LTTS’ IoT capabilities identified its wide IoT services portfolio which include IoT Platforms and connectivity services, connected devices and ER&D services for Smart Manufacturing.

Some of the key IoT solutions that have been deployed in LTTS’ global customer projects include:

  1. WAGES, LTTS’ Cloud-based utility usage monitoring solution that is specifically designed to help plant managers collect consumption data from across locations and visualize them as KPIs through a unified dashboard. WAGES refers to Water, Air, Gas Electricity and Steam, the key inputs in a manufacturing process that are tracked & monitored by the solution.
  2. LTTS has developed a Remote Asset Performance Management Solution for a Construction Major which intends to cover 30 thousand assets across 500 asset types leading to an expected 12% improvement in asset utilization and reduced costs as on-time asset availability improve.
  3. LTTS’ Personal Protection Equipment Solution includes IoT-enabled Personal Protective gear, an example of advanced wearable technology for industrial usage, that employs a Zigbee interface mechanism whereby alerts and notifications are sent to both personnel’s and their supervisors in case of any breach.

Additionally, NelsonHall identified key strengths of LTTS which include:

  • Background in smart manufacturing, an area where IoT demand stems from
  • Credibility in elements of IoT services, namely embedded systems, mechanical engineering, connectivity and telecom services
  • Financial capabilities to invest in IoT offerings
  • Development of proprietary IP

NelsonHall noted that LTTS is investing in developing IP use cases and creating Intellectual Assets that are reusable like the smart building framework i-BEMS that enables ‘Net-Zero,’ energy generation management in buildings.

About L&T Technology Services Limited:

L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 52 Fortune 500 companies and 48 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have around 11,000 employees spread across 15 global delivery centers, 28 global sales offices and 38 innovation labs in India as of September 30, 2017.

For additional information about L&T Technology Services log on to

About NelsonHall:

NelsonHall is the leading global analyst firm dedicated to helping organizations understand the ‘art of the possible’ in next generation IT and business services. With analysts in the U.S., U.K., and Continental Europe, NelsonHall provides buy-side organizations with detailed, critical information on markets and vendors that helps them make fast and highly informed sourcing decisions. And for vendors, NelsonHall provides deep knowledge of market dynamics and user requirements to help them hone their go-to-market strategies. NelsonHall’s research is rigorous and all-original, and widely respected for the quality, depth and insight of its analysis.

Contact information

L&T Technology Services Limited
Aniruddha Basu, +91-80-67675173

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 07:00Pressemelding

SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre

Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00Pressemelding

The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements

Elliott Advisors (UK) Limited Statement on Telecom Italia23.3.2018 07:00Pressemelding

Given the momentum behind Elliott's campaign at Telecom Italia to improve both performance and governance, Elliott was not surprised to see yesterday's resignation of seven board members affiliated with Vivendi. Unable to advance any meritorious arguments, the Board has simply abandoned their posts to stall for time. Elliott regards this action as cynical and self-serving, in that it delays the ability of Telecom Italia shareholders to express their votes at the upcoming AGM. This is yet another example of minority shareholder rights at Telecom Italia being abrogated and the continued disregard of corporate governance best practice. Finally, Vivendi should note Elliott's forty-year track record of consistent value creation, and sustained, long-term commitments to expose poor governance and catalyse positive change; Elliott's investment history in Telecom Italia dates back to 1999, well before Vivendi became a shareholder in the Company. About Elliott Elliott Management Corporation mana

Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma23.3.2018 06:00Pressemelding

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) provided a positive opinion for Cabometyx® (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma (aRCC).The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, Executive Vice President, R&D and Chief Scientific Officer said: “Today’s positive opinion from the CHMP is important news for patients with previously untreated advanced renal cell carcinoma, who can shortly benefit from Cabometyx ® as a new first-line treatment option. Following the evidence of its clinical value after a prior VEGF-targeted treatment, we are pleased to be able to expand the benefit of Cabometyx ® for treatment-naïve patients wit